gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

The treatment of brain cancer with Drug-Nanoparticle complex

Meeting Abstract

  • corresponding author presenting/speaker Sunita Singh - Otto-von-Guericke Universität, Magdeburg, Deutschland
  • S. Singh - Otto-von-Guericke Universität, Magdeburg
  • A. Bouazzaoui - Otto-von-Guericke Universität, Magdeburg
  • Julia Kubasch - NanoDel Technologies GmbH, Magdeburg
  • H.-E. Radunz - NanoDel Technologies GmbH, Magdeburg
  • B.A. Sabel - Otto-von-Guericke Universität, Magdeburg

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPE462

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Singh et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



The blood-brain barrier protects the brain against toxic substances that circulate in the bloodstream. It is formed by the endothelium of the brain vessels, the basal membrane and the neuroglial cells which makes it difficult to medicate patients with brain diseases such as Glioblastoma. However, we were able to bypass the blood-brain barrier with Polybutylcyano-acrylate-Nanoparticles (PBCA). These Nanoparticles have an average diameter size of about 100-300 nm and are very rapidly biodegraded. In our studies we found, that drugs like Doxorubicin loaded on Nanoparticles can increase the survive of rats suffering from brain cancer. The optimal amount of Doxorubicin Nanoparticle complexes lies between 4.5 and 7.5mg/kg relative to the weight of the rat.